Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
RANCHO CORDOVA, Calif., Sept. 05, 2017 -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Jeffery Cauble, principal accounting officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12, 2017 at 8:20am ET. The conference is being held September 10-12 at the Lotte New York Palace Hotel in New York City.
A live webcast of the presentation will be available on the Events and Presentations page of the company’s website: www.cescatherapeutics.com. The webcast will be archived for 90 days.
About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.
Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics’ annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc. Wendy Samford 916-858-5191 [email protected] Investor Contact: Rx Communications Paula Schwartz 917-322-2216 [email protected]
